Studies on Agents with Mixed NO-dependent Vasodilating and Beta-blocking Activities

Overview

Journal Pharm Res

Specialties Pharmacology
Pharmacy

Date 1998 Feb 7

PMID 9453064

Citations 5

Authors

D Boschi

A Di Stilo

C Cena

M Lolli

R Fruttero

A Gasco

Affiliations

Soon will be listed here.

Abstract

Purpose: A series of derivatives having a propranolol-like moiety linked to NO-donor furoxan substructures were synthesized. The main objective of this investigation was to obtain agents with mixed NO-dependent vasodilating and beta-blocking activities.

Methods: Most of the target compounds were synthesized from the appropriate furoxans bearing XCH2CH2NH2 (X = O, S, SO2) chains at the 4 position of the ring, using Al(C2H5)3 in methylene chloride solution and (+/-)2,3-epoxypropyl 1-naphtyl ether. Two of the final products (X = CONH) were obtained by coupling the appropriate furoxancarboxylic acids with N-[2-hydroxy-3-(1-naphthoxy)propyl]-ethylenediamine. beta 1- and beta 2-blocking activities were examined on isolated guinea pig right atria and on guinea pig trachea respectively. Vasodilating properties were assessed on endothelium denuded strips of rat aorta.

Results: Some derivatives behave as well balanced "hybrids" displaying NO-dependent vasodilating and beta-blocking properties in the same concentration range. Some others display either prevalent beta-blocking or vasodilating activity. Generally speaking hybrid formation lowers the affinity for beta-receptors, in particular for beta 2-type, to give an increase in beta 1/beta 2 selectivity.

Conclusions: The furoxan system is a flexible tool in designing analogues of propranolol whose NO-donating and beta-blocking properties are modulated over a wide range.

Citing Articles

Anti-Proliferative Properties of the Novel Hybrid Drug Met-ITC, Composed of the Native Drug Metformin with the Addition of an Isothiocyanate HS Donor Moiety, in Different Cancer Cell Lines.

Citi V, Barresi E, Piragine E, Spezzini J, Testai L, Da Settimo F Int J Mol Sci. 2023; 24(22).

PMID: 38003321 PMC: 10671447. DOI: 10.3390/ijms242216131.

New praziquantel derivatives containing NO-donor furoxans and related furazans as active agents against Schistosoma mansoni.

Guglielmo S, Cortese D, Vottero F, Rolando B, Kommer V, Williams D Eur J Med Chem. 2014; 84:135-45.

PMID: 25016371 PMC: 4160910. DOI: 10.1016/j.ejmech.2014.07.007.

Furoxans (1,2,5-oxadiazole-N-oxides) as novel NO mimetic neuroprotective and procognitive agents.

Schiefer I, VandeVrede L, Fa M, Arancio O, Thatcher G J Med Chem. 2012; 55(7):3076-87.

PMID: 22429006 PMC: 3407596. DOI: 10.1021/jm201504s.

Recent developments in nitric oxide donor drugs.

Miller M, Megson I Br J Pharmacol. 2007; 151(3):305-21.

PMID: 17401442 PMC: 2013979. DOI: 10.1038/sj.bjp.0707224.

Studies on agents with mixed NO-dependent and calcium channel antagonistic vasodilating activities.

Cena C, Visentin S, Di Stilo A, Boschi D, Fruttero R, Gasco A Pharm Res. 2001; 18(2):157-65.

PMID: 11405285 DOI: 10.1023/a:1011072116210.

References

Sorba G, Medana C, Fruttero R, Cena C, Di Stilo A, Galli U . Water soluble furoxan derivatives as NO prodrugs. J Med Chem. 1997; 40(4):463-9. DOI: 10.1021/jm960379t. View

Gasco A, Fruttero R, Sorba G . No-donors: an emerging class of compounds in medicinal chemistry. Farmaco. 1996; 51(10):617-35. View

Hecker M, Vorhoff W, Bara A, Mordvintcev P, Busse R . Characterization of furoxans as a new class of tolerance-resistant nitrovasodilators. Naunyn Schmiedebergs Arch Pharmacol. 1995; 351(4):426-32. DOI: 10.1007/BF00169084. View

Fruttero R, Boschi D, Di Stilo A, Gasco A . The furoxan system as a useful tool for balancing "hybrids" with mixed alpha 1-antagonist and NO-like vasodilator activities. J Med Chem. 1995; 38(25):4944-9. DOI: 10.1021/jm00025a012. View

Medana C, Ermondi G, Fruttero R, Di Stilo A, Ferretti C, Gasco A . Furoxans as nitric oxide donors. 4-Phenyl-3-furoxancarbonitrile: thiol-mediated nitric oxide release and biological evaluation. J Med Chem. 1994; 37(25):4412-6. DOI: 10.1021/jm00051a020. View

Lancaster Jr J . Simulation of the diffusion and reaction of endogenously produced nitric oxide. Proc Natl Acad Sci U S A. 1994; 91(17):8137-41. PMC: 44560. DOI: 10.1073/pnas.91.17.8137. View

Feelisch M, Schonafinger K, Noack E . Thiol-mediated generation of nitric oxide accounts for the vasodilator action of furoxans. Biochem Pharmacol. 1992; 44(6):1149-57. DOI: 10.1016/0006-2952(92)90379-w. View

Bohn H, Brendel J, Martorana P, Schonafinger K . Cardiovascular actions of the furoxan CAS 1609, a novel nitric oxide donor. Br J Pharmacol. 1995; 114(8):1605-12. PMC: 1510397. DOI: 10.1111/j.1476-5381.1995.tb14946.x. View

Ferioli R, Folco G, Ferretti C, Gasco A, Medana C, Fruttero R . A new class of furoxan derivatives as NO donors: mechanism of action and biological activity. Br J Pharmacol. 1995; 114(4):816-20. PMC: 1510189. DOI: 10.1111/j.1476-5381.1995.tb13277.x. View

10.

Kerwin Jr J, Lancaster Jr J, Feldman P . Nitric oxide: a new paradigm for second messengers. J Med Chem. 1995; 38(22):4343-62. DOI: 10.1021/jm00022a001. View

11.

Ghigo D, Heller R, Calvino R, Alessio P, Fruttero R, Gasco A . Characterization of a new compound, S35b, as a guanylate cyclase activator in human platelets. Biochem Pharmacol. 1992; 43(6):1281-8. DOI: 10.1016/0006-2952(92)90504-c. View

12.

Atlas D, Steer M, Levitzki A . Affinity label for beta-adrenergic receptor in turkey erythrocytes. Proc Natl Acad Sci U S A. 1976; 73(6):1921-5. PMC: 430419. DOI: 10.1073/pnas.73.6.1921. View

13.

van Zwieten P . Hybrid or multifactorial drugs in antihypertensive treatment. J Hypertens. 1990; 8(8):687-96. DOI: 10.1097/00004872-199008000-00001. View